In Brief: Delcath Systems Inc.
Tuesday, November 18 2008 | Comments
What's This?
Delcath Systems Inc. received two orphan drug designations from the Food and Drug Administration for melphalan--one as a potential treatment for cutaneous melanoma and the other for ocular melanoma. The company is enrolling patients in a Phase III clinical trial to test its proprietary drug delivery system, known as percutaneous hepatic perfusion (PHP), in conjunction with melphalan to treat ocular and cutaneous melanoma metastatic to the liver. Print |
E-mail | 
Add this to PeerClip
Comments
Be the first to write a comment for this article!
You must be logged in to post a comment.
- AISRS useful in measuring methylphenidate therapy for adults with ADHD
- Pioglitazone prevents progression of coronary atherosclerosis in patients with CAD, diabetes
- CARISMA researchers use ILR to document arrhythmias in post-MI patients with low ejection fraction, identify high-degree AV block as independent predictor of cardiac death
- Adalimumab improves peripheral arthritis, enthesitis, axial signs, symptoms of AS in patients with long-standing disease treated in real-life practice, researchers report
- Experts discuss ENHANCE trial data, implications for clinical practice
- Radiotherapy, chemotherapy increase risks of second malignancy, cardiovascular disease similar to smoking in patients with testicular cancer, researchers report
- Lipid-modifying drugs may decrease all-cause, cardiovascular-specific mortality in patients on peritoneal dialysis, study data suggest
- Careful discharge planning, follow-up vital for high-risk neonates facing hospital discharge, updated AAP guidelines state
- New directions for pharmacologic treatment of insomnia
- ACE inhibitors, ARBs may reduce risk of nonmelanoma skin cancer in high-risk patients, researchers report
All material on this Web site is protected by copyright. Copyright © 1994-2009 by VerusMed, a ConnectivHealth company. This Web site may also contain material copyrighted by third parties.